Výsledky vyhledávání

The use of partially HLA-mismatched donors for allogeneic transplantation in patients with mucopolysaccharidosis-I

Autor: D R, Fleming, P J, Henslee-Downey, G, Ciocci, E H, Romond, E, Marciniak, R K, Munn, J S, Thompson

Publikováno v: Pediatric transplantation. 2(4)

Allogeneic bone marrow transplantation (BMT) from an HLA-matched sibling appears to improve survival and diminish some of the physiologic derangements seen in children with mucopolysaccharidosis (MPS)-I (Hurler Syndrome), an inherited metabolic stora

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::57d6ec6a413913f36982d0c89bf97cbd
https://pubmed.ncbi.nlm.nih.gov/10084724

Zobrazit plný text záznamu

Treatment of leukemia with partially matched related bone marrow transplantation

Autor: Thompson Js, Munn Rk, Mary Kay Rayens, Messino Mj, EJ Harder, Fleming, Henslee-Downey Pj, Gordon L. Phillips, J S Macdonald, E H Romond, Marciniak E

Publikováno v: Bone marrow transplantation. 19(5)

The results of partially matched related donor (PMRD) marrow transplantation for 82 patients with leukemia are reported, including 45 who received two antigen disparate grafts. Following intensive radiochemotherapy, patients received grafts which wer

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::652e5adbf403462cd5b141f53ec3d335
https://pubmed.ncbi.nlm.nih.gov/9052906

Zobrazit plný text záznamu

Long-term survival in advanced chronic myelogenous leukemia following bone marrow transplantation from haploidentical related donors

Autor: M R, Bishop, P J, Henslee-Downey, J R, Anderson, E H, Romond, E, Marciniak, R, Yankey, M, Reeves, J S, Thompson

Publikováno v: Bone marrow transplantation. 18(4)

From 1987 to 1991, 26 patients with CML and a median age of 31 years received allogeneic BMT from a partially mismatched related donor (PMRD) who shared at least one haplotype with the recipient. Nine patients were in accelerated phase (AP), and 11 p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::70597c9d486cff4ba2324f64e9ca4c04
https://pubmed.ncbi.nlm.nih.gov/8899190

Zobrazit plný text záznamu

Allogeneic bone marrow transplantation with T cell-depleted partially matched related donors for advanced acute lymphoblastic leukemia in children and adults: a comparative matched cohort study

Autor: D R, Fleming, P J, Henslee-Downey, E H, Romond, E J, Harder, E, Marciniak, R K, Munn, M J, Messino, J S, Macdonald, M, Bishop, M K, Rayens, J S, Thompson, K A, Foon

Publikováno v: Bone marrow transplantation. 17(6)

Allogeneic BMT provides the best treatment currently available for long-term disease-free survival in patients with recurrent ALL. Historically, partially matched related donors provided the opportunity for treatment to a greater number of patients t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::c4a47e527652b64547c6a3c4f27f0720
https://pubmed.ncbi.nlm.nih.gov/8807094

Zobrazit plný text záznamu

Update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)→paclitaxel (T) vs. AC→T with trastuzumab (H)

Autor: C. E. Geyer, J. L. Bryant, E. H. Romond, M. S. Ewer, D. L. Keefe, R. P. Shannon, T. B. Levine, P. Rastogi, S. M. Swain, N. Wolmark

Publikováno v: Journal of Clinical Oncology. 24:581-581

581 Trastuzumab (H) has been shown to improve 3-year disease-free survival (DFS) and overall survival (OS) in HER2 positive, node-positive breast cancer patients when combined with paclitaxel (T) following AC (Romond NEJM 2005:353;1673–1684). Cardi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1ab18550e38d1107324753c604b34f6a
https://doi.org/10.1200/jco.2006.24.18_suppl.581

Zobrazit plný text záznamu

Cardiac safety analysis of the first stage of NSABP B-31, a randomized trial comparing the safety and efficacy of doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) to that of AC followed by paclitaxel plus trastuzumab (TH) in patients (pts) with operable, node-positive (N+), HER-2 overexpressing breast cancer (HER2+BC)

Autor: D Keefe, J Bryant, E Tan-Chiu, M Ewer, Norman Wolmark, Charles E. Geyer, R Shannon, G Yothers, E. H. Romond

Publikováno v: European Journal of Cancer Supplements. 2:141

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5f79babf78ae8ffe663fd5b5df31d450
https://doi.org/10.1016/s1359-6349(04)90895-6

Zobrazit plný text záznamu

A new approach to the prevention of graft-versus-host disease using XomaZyme-H65 following histo-incompatible partially T-depleted marrow grafts

Autor: P J, Henslee, V S, Byers, C D, Jennings, E, Marciniak, J S, Thompson, J S, Macdonald, E H, Romond, M J, Messino, P J, Scannon

Publikováno v: Transplantation proceedings. 21(1 Pt 3)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::cca35271fed553a706810e69e987d433
https://pubmed.ncbi.nlm.nih.gov/2650413

Zobrazit plný text záznamu

Catabolism and distribution of functionally heterogeneous human antithrombin III

Autor: E, Marciniak, E H, Romond

Publikováno v: The Journal of laboratory and clinical medicine. 109(1)

To test the hypothesis that binding to an endogenous heparin-like substance controls breakdown of antithrombin III (ATIII) in vivo, the metabolic behavior of a commercial ATIII concentrate was investigated in three normal volunteers and five subjects

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::9313b21cac8f7724ef7ada4d98cc1801
https://pubmed.ncbi.nlm.nih.gov/3794520

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání